Table of Content

Table of Contents

Global Community-acquired Bacterial Pneumonia Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Community-acquired Bacterial Pneumonia Market by Value
2.2.1 Global Community-acquired Bacterial Pneumonia Revenue by Type
2.2.2 Global Community-acquired Bacterial Pneumonia Market by Value (%)
2.3 Global Community-acquired Bacterial Pneumonia Market by Production
2.3.1 Global Community-acquired Bacterial Pneumonia Production by Type
2.3.2 Global Community-acquired Bacterial Pneumonia Market by Production (%)

3. The Major Driver of Community-acquired Bacterial Pneumonia Industry
3.1 Historical & Forecast Global Community-acquired Bacterial Pneumonia Demand
3.2 Largest Application for Community-acquired Bacterial Pneumonia (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Community-acquired Bacterial Pneumonia Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Community-acquired Bacterial Pneumonia Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Community-acquired Bacterial Pneumonia Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Community-acquired Bacterial Pneumonia Average Price Trend
12.1 Market Price for Each Type of Community-acquired Bacterial Pneumonia in US (2018-2022)
12.2 Market Price for Each Type of Community-acquired Bacterial Pneumonia in Europe (2018-2022)
12.3 Market Price for Each Type of Community-acquired Bacterial Pneumonia in China (2018-2022)
12.4 Market Price for Each Type of Community-acquired Bacterial Pneumonia in Japan (2018-2022)
12.5 Market Price for Each Type of Community-acquired Bacterial Pneumonia in India (2018-2022)
12.6 Market Price for Each Type of Community-acquired Bacterial Pneumonia in Korea (2018-2022)
12.7 Market Price for Each Type of Community-acquired Bacterial Pneumonia in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Community-acquired Bacterial Pneumonia Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Community-acquired Bacterial Pneumonia

14. Community-acquired Bacterial Pneumonia Competitive Landscape
14.1 Nabriva Therapeutics
14.1.1 Nabriva Therapeutics Company Profiles
14.1.2 Nabriva Therapeutics Product Introduction
14.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Paratek Pharmaceuticals
14.2.1 Paratek Pharmaceuticals Company Profiles
14.2.2 Paratek Pharmaceuticals Product Introduction
14.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Melinta Therapeutics
14.3.1 Melinta Therapeutics Company Profiles
14.3.2 Melinta Therapeutics Product Introduction
14.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Allergan plc
14.4.1 Allergan plc Company Profiles
14.4.2 Allergan plc Product Introduction
14.4.3 Allergan plc Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Bayer AG
14.5.1 Bayer AG Company Profiles
14.5.2 Bayer AG Product Introduction
14.5.3 Bayer AG Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Lupin Pharmaceuticals
14.6.1 Lupin Pharmaceuticals Company Profiles
14.6.2 Lupin Pharmaceuticals Product Introduction
14.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Mylan N.V.
14.7.1 Mylan N.V. Company Profiles
14.7.2 Mylan N.V. Product Introduction
14.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Sanofi S.A.
14.8.1 Sanofi S.A. Company Profiles
14.8.2 Sanofi S.A. Product Introduction
14.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Pfizer Inc.
14.9.1 Pfizer Inc. Company Profiles
14.9.2 Pfizer Inc. Product Introduction
14.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Dainippon Sumitomo Pharma
14.10.1 Dainippon Sumitomo Pharma Company Profiles
14.10.2 Dainippon Sumitomo Pharma Product Introduction
14.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Takeda Pharmaceutical Company Limited
14.12 Basilea Pharmaceutica International AG
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Community-acquired Bacterial Pneumonia Industry (Volume)
Figure 2. Community-acquired Bacterial Pneumonia Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Community-acquired Bacterial Pneumonia Revenue in 2022
Figure 5. US Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Community-acquired Bacterial Pneumonia Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Community-acquired Bacterial Pneumonia Revenue, by Type (Million USD) (2018-2028)
Table 4. Community-acquired Bacterial Pneumonia Production, by Type (K Unit) (2018-2028)
Table 5. Community-acquired Bacterial Pneumonia Demand (K Unit) by Application (2018-2028)
Table 6. Community-acquired Bacterial Pneumonia Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Community-acquired Bacterial Pneumonia Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Community-acquired Bacterial Pneumonia Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Community-acquired Bacterial Pneumonia in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Nabriva Therapeutics Profiles
Table 61. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Introduction
Table 62. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Nabriva Therapeutics Strategic initiatives
Table 64. Paratek Pharmaceuticals Profiles
Table 65. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Introduction
Table 66. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Paratek Pharmaceuticals Strategic initiatives
Table 68. Melinta Therapeutics Profiles
Table 69. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Introduction
Table 70. Melinta Therapeutics Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Melinta Therapeutics Strategic initiatives
Table 72. Allergan plc Profiles
Table 73. Allergan plc Community-acquired Bacterial Pneumonia Product Introduction
Table 74. Allergan plc Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Allergan plc Strategic initiatives
Table 76. Bayer AG Profiles
Table 77. Bayer AG Community-acquired Bacterial Pneumonia Product Introduction
Table 78. Bayer AG Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Bayer AG Strategic initiatives
Table 80. Lupin Pharmaceuticals Profiles
Table 81. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Introduction
Table 82. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Lupin Pharmaceuticals Strategic initiatives
Table 84. Mylan N.V. Profiles
Table 85. Mylan N.V. Community-acquired Bacterial Pneumonia Product Introduction
Table 86. Mylan N.V. Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. Mylan N.V. Strategic initiatives
Table 88. Sanofi S.A. Profiles
Table 89. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Introduction
Table 90. Sanofi S.A. Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Sanofi S.A. Strategic initiatives
Table 92. Pfizer Inc. Profiles
Table 93. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Introduction
Table 94. Pfizer Inc. Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Pfizer Inc. Strategic initiatives
Table 97. Dainippon Sumitomo Pharma Profiles
Table 98. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Introduction
Table 99. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Dainippon Sumitomo Pharma Strategic initiatives
Table 101. Takeda Pharmaceutical Company Limited Profiles
Table 102. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Introduction
Table 103. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Takeda Pharmaceutical Company Limited Strategic initiatives
Table 105. Basilea Pharmaceutica International AG Profiles
Table 106. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Introduction
Table 107. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Production (Unit), Revenue (Million USD) (2018-2022)
Table 108. Basilea Pharmaceutica International AG Strategic initiatives